We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Link Found Between Immune System and Lymphoma

By LabMedica International staff writers
Posted on 12 Dec 2017
Classical Hodgkin lymphoma (cHL) is a lymphoid malignancy of germinal center (GC) B-cell origin, which is characterized by Hodgkin and Reed–Sternberg (HRS) cells with a dominant background population of reactive inflammatory cells.

People who inherit genetic changes that alter the function of their immune system are at increased risk of developing Hodgkin lymphoma. Of the four major subtypes of cHL, nodular sclerosis Hodgkin lymphoma (NSHL) and mixed cellularity Hodgkin lymphoma (MCHL) account for 65% and 20% of cHL, respectively.

Image: A diagram of the Kompetitive Allele Specific Polymerase Chain Reaction (PCR KASP) method (Photo courtesy of J.P. Livingstone).
Image: A diagram of the Kompetitive Allele Specific Polymerase Chain Reaction (PCR KASP) method (Photo courtesy of J.P. Livingstone).

A large group of scientists collaborating with The Institute of Cancer Research (London, UK) analyzed genetic data from 5,314 cases of Hodgkin lymphoma and 16,749 controls, from four different European studies. They analyzed constitutional DNA from 1,717 cases, which were genotyped using the Illumina Oncoarray (Illumina Inc, San Diego, CA, USA). The fidelity of genome-wide association study (GWAS) imputation was assessed by the concordance between imputed and directly genotyped single nucleotide polymorphisms (SNP) in a subset of samples. Replication genotyping of UK samples was performed using Polymerase Chain Reaction Kompetitive Allele Specific (PCR KASP) chemistry.

The investigators identified six new single-letter changes in DNA that were linked to the development of Hodgkin lymphoma and five of these affect the way a type of white blood cell, called B cells, develop. The study also showed clear differences in genetic risk between two different subtypes of Hodgkin Lymphoma and NSHL and MCHL. For example, a single-letter change located in DNA near the gene LIM Domain Containing Preferred Translocation Partner In Lipoma (LPP) increased the risk of NSHL by 37%, but had little effect on the risk of developing MCHL.

Richard S. Houlston, FMedSci, FRS, a Professor of Molecular and Population Genetics and senior author of the study, said, “Hodgkin lymphoma is a cancer of immune cells called B cells, and our study links the risk of the disease to changes in the genes that control how B cells develop. Interestingly, we found that some of the genetic changes we have linked to Hodgkin lymphoma have previously been associated with the risk of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The new information could point towards new ways of diagnosing, treating, or even helping to prevent Hodgkin lymphoma.” The study was published on December 1, 2017, in the journal Nature Communications.

Related Links:
The Institute of Cancer Research
Illumina Oncoarray



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Latest Hematology News

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy